TY  - JOUR 
AU  - Pombo Suárez, Manuel
AU  - Seoane-Mato, D.
AU  - Díaz-González, F.
AU  - Cea-Calvo, L.
AU  - Sánchez-Alonso, F.
AU  - Sánchez-Jareño, M.
AU  - Jovani, V.
AU  - García-Magallón, B.
AU  - Martínez-González, O.
AU  - Campos-Fernández, C.
AU  - Manero, J.
AU  - Díaz-Torne, C.
AU  - Bohórquez, C.
AU  - Ros-Vilamajó, I.
AU  - Pérez-Vera, Y.
AU  - Castrejón, I.
PY  - 2023
SN  - 1557-0681
UR  - http://hdl.handle.net/20.500.11940/21688
AB  - Aim: To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors. Methods: Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started...
LA  - eng
KW  - Adult
KW  - Humans
KW  - Arthritis, Psoriatic
KW  - Spondylarthritis
KW  - Retrospective Studies
KW  - Arthritis, Rheumatoid
KW  - Axial Spondyloarthritis
KW  - Antirheumatic Agents
KW  - Treatment Outcome
TI  - Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis
DO  - 10.1002/msc.1684
T2  - Musculoskeletal Care
M2  - 189
KW  - AS Santiago
KW  - CHUS
VL  - 21
ER  -